Academic pharmacist Nataly Martini provides key information on Helicobacter pylori pathophysiology, diagnosis and evidence-based treatment strategies to enhance patient outcomes
Wednesday 12 March 2025, 12:55 AM
14 minutes to Read
More aggressive secondary prevention of cardiovascular disease now funded
+Educate
In print
Cardiovascular health
More aggressive secondary prevention of cardiovascular disease now funded
Friday 1 April 2022, 12:45 AM
[Image: iStock.com – Rasi Bhadramani]
Consultant cardiologist Chris Ellis discusses the recent funding of rosuvastatin, focusing on its use for secondary prevention of cardiovascular disease
Key points, Rosuvastatin 40mg will lower the LDL cholesterol level by approximately 63 per cent, compared with about 55 per cent with atorvastatin 80mg.
Ezetimi, Education Blue W/ Grey Background W/ Padding
Kia ora and welcome to Pharmacy Today Kaitiaki Rongoā O Te Wā
Not a subscriber? Unlock this article by subscribing here.
References
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):11188.
Class
Hosted Content 2
Why recognising the signs of dehydration is important...
Saturday 1 February 2025, 08:30 AM
2 minutes to Read
Latest issue
